Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress

BACKGROUND: The anticancer properties of aspirin are restricted by its gastrointestinal toxicity and its limited efficacy. Therefore, we synthesized phospho-aspirin (PA-2; MDC-22), a novel derivative of aspirin, and evaluated its chemotherapeutic and chemopreventive efficacy in preclinical models of...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Liqun, Wong, Chi C, Mackenzie, Gerardo G, Sun, Yu, Cheng, Ka Wing, Vrankova, Kvetoslava, Alston, Ninche, Ouyang, Nengtai, Rigas, Basil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941604/
https://www.ncbi.nlm.nih.gov/pubmed/24575839
http://dx.doi.org/10.1186/1471-2407-14-141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941604/
https://www.ncbi.nlm.nih.gov/pubmed/24575839
http://dx.doi.org/10.1186/1471-2407-14-141

Ejemplares similares